Evidence for a shift to anaerobic metabolism in adipose tissue in efavirenz-containing regimens for HIV with different nucleoside backbones.

Evidence for a shift to anaerobic metabolism in adipose tissue in efavirenz-containing regimens for HIV with different nucleoside backbones.

BACKGROUND: Antiretroviral (ARV) treatment has been associated with abnormalities in lipid and mitochondrial metabolism. We compared patterns of gene expression in the subcutaneous adipose tissue (SAT) of HIV-positive subjects before and after 18-24 months of ARV therapy with HIV-negative controls....

Full description

Bibliographic Details
Main Authors:	McGee, K, Shahmanesh, M, Boothby, M, Nightingale, P, Gathercole, L, Tripathi, G, Harte, A, Shojaee-Moradie, F, Umpleby, A, Das, S, Al-Daghri, N, McTernan, P, Tomlinson, J
Format:	Journal article
Language:	English
Published:	2012

Similar Items

Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months.
by: Boothby, M, et al.
Published: (2009)

HIV infection significantly reduces lipoprotein lipase which remains low after 6 months of antiretroviral therapy
by: Boothby, M, et al.
Published: (2008)

Adipocyte mitochondrial gene expression following 18-24 months treatment with zidovidine or tenofovir-containing antiretroviral therapy
by: McGee, K, et al.
Published: (2009)

Changes in the adipocyte (lipid and glucose metabolism) gene expression following 18-24 months treatment with ZDV or TDF-containing ART; and adipocyte mitochondrial gene expression
by: Gathercole, L, et al.
Published: (2009)

The effect of antiretroviral therapy on genes involved with glucose and lipid metabolism
by: Boothby, M, et al.
Published: (2007)

The effect of antiretroviral therapy on genes involved with mitochondrial function
by: Boothby, M, et al.
Published: (2007)

Complications of HIV Disease or Treatment
by: Shahmanesh, M, et al.
Published: (2010)

Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens
by: Pobiner Bonnie F, et al.
Published: (2005-04-01)

Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients
by: Restelli U, et al.
Published: (2017-06-01)

How will AI make sense of our messy lives and improve our mental health?
by: Jan Speechley, et al.
Published: (2024-01-01)

Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models
by: Mastan SK, et al.
Published: (2009-10-01)

HIV Non-Nucleoside Reverse Transcriptase Inhibitor Efavirenz Reduces Neural Stem Cell Proliferation in Vitro and in Vivo
by: Jingji Jin, et al.
Published: (2016-11-01)

RNAfitme: a webserver for modeling nucleobase and nucleoside residue conformation in fixed-backbone RNA structures
by: Maciej Antczak, et al.
Published: (2018-08-01)

Efavirenz Has the Highest Anti-Proliferative Effect of Non-Nucleoside Reverse Transcriptase Inhibitors against Pancreatic Cancer Cells.
by: Markus Hecht, et al.
Published: (2015-01-01)

Visfatin is regulated by rosiglitazone in type 2 diabetes mellitus and influenced by NFκB and JNK in human abdominal subcutaneous adipocytes.
by: Kirsty C McGee, et al.
Published: (2011-01-01)

The numerical solution of equations /
by: 308704 Balfour, A., et al.
Published: (1967)

Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review.
by: George W Rutherford, et al.
Published: (2016-01-01)

The evidence for using tenofovir disoproxil fumarate plus lamivudine as a nucleoside analogue backbone for the treatment of HIV
by: Laura Waters, et al.
Published: (2021-03-01)

Differential adipose tissue gene expression profiles in abacavir treated patients that may contribute to the understanding of cardiovascular risk: a microarray study.
by: Mohsen Shahmanesh, et al.
Published: (2015-01-01)

Efavirenz in pregnancy
by: Polly Clayden, et al.
Published: (2010-11-01)

Relationship of serum adiponectin and resistin to glucose intolerance and fat topography in south-Asians
by: Barnett A H, et al.
Published: (2006-05-01)

Serum resistin is associated with C-reactive protein and LDL- cholesterol in type 2 diabetes and coronary artery disease in a Saudi population
by: Al-Attas O, et al.
Published: (2005-07-01)

Electroencephalography as a diagnostic tool for late-onset efavirenz neurotoxicity syndrome.
by: Sam Nightingale, et al.
Published: (2023-01-01)

Virtual screening, molecular docking studies and DFT calculations of FDA approved compounds similar to the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz
by: Maryam A. Jordaan, et al.
Published: (2020-08-01)

Detection, control, and renovation of contaminated ground water /
by: 175905 Dee, Norbert, et al.
Published: (1987)

Efavirenz-induced urolithiasis.
by: Wirth, G, et al.
Published: (2006)

Efavirenz and neuropsychiatric effects
by: Mukesh Dheda
Published: (2017-04-01)

Development of reverse phase high-performance liquid chromatographic method for the estimation of HIV non-nucleoside reverse transcriptase inhibitor drug efavirenz in the rat brain
by: Smita Prakash Kakad, et al.
Published: (2021-01-01)

Modular isoquinoline synthesis using catalytic enolate arylation and in situ functionalization.
by: Pilgrim, B, et al.
Published: (2013)

Effects of a multi-strain probiotic supplement for 12 weeks in circulating endotoxin levels and cardiometabolic profiles of medication naïve T2DM patients: a randomized clinical trial
by: Shaun Sabico, et al.
Published: (2017-12-01)

Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study
by: Hodson, L, et al.
Published: (2017)

Revisiting efavirenz in the era of dolutegravir: Low-dose efavirenz, a viable alternative capable of holding its own against dolutegravir-based regimens
by: Sumit Arora, et al.
Published: (2023-01-01)

Efavirenz: History, Development and Future
by: Bárbara Costa, et al.
Published: (2022-12-01)

Backbone
by: Brandon Wint
Published: (2022-10-01)

The Effect of Fructose Feeding on Intestinal Triacylglycerol Production and De Novo Fatty Acid Synthesis in Humans
by: Simon Steenson, et al.
Published: (2020-06-01)

The fat mass and obesity-associated (FTO) gene allele rs9939609 and glucose tolerance, hepatic and total insulin sensitivity, in adults with obesity.
by: Ann Kristin Hjelle de Soysa, et al.
Published: (2021-01-01)

backbone: An R package to extract network backbones.
by: Zachary P Neal
Published: (2022-01-01)

backbone: An R package to extract network backbones
by: Zachary P. Neal
Published: (2022-01-01)

Structural basis of nucleoside and nucleoside drug selectivity by concentrative nucleoside transporters
by: Zachary Lee Johnson, et al.
Published: (2014-07-01)

Influence of the Efavirenz Micronization on Tableting and Dissolution
by: Lucio Mendes Cabral, et al.
Published: (2012-09-01)